About the Malignant Cancer Session
Malignant cancer is a type of skin cancer that is often seen in people who have had sun damage in the form of sunburns, tanning, or prolonged ultraviolet radiation exposure. It is characterized by uncontrolled growth of abnormal cells in the skin that spread rapidly and can lead to the death of healthy or nearby skin. Malignant skin cancer is the most dangerous type of skin cancer as it has the greatest potential to spread to other areas of the body and become life threatening. It is the deadliest form of the 3 major skin cancers: basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. The primary risk factor for malignant skin cancer is ultraviolet radiation from the sun or tanning beds, although it can also form in areas that have had radiation therapy or long-term exposure to arsenic or industrial chemicals. Certain genetic mutations can also increase the risk of developing this cancer. The most common symptom of malignant skin cancer is the appearance of a growth on the skin that may be raised, scaly, and red or dark in color. Other symptoms may include itching or pain, an ulcer or sore that won’t heal, or changes in mole size. If you suspect you may have malignant skin cancer, it’s important to seek medical attention immediately. Diagnosis must be made promptly as delaying can reduce the chance of recovery or increase the risk of death. After physical examination and biopsy, the doctor can identify the type and grade of the cancer and accurately assess its stage. Once identified, the treatment plan must be tailored according to the stage of the cancer and other factors. Surgery is the most common method of treatment and may be supplemented with radiation, chemotherapy, immunotherapy, or clinical trials. With early diagnosis and prompt treatment, malignant skin cancer can be successfully managed. Although there is no way to completely prevent it, it is important to protect yourself from ultraviolet radiation exposure whenever possible.
Featured Speakers — Malignant Cancer 2027
Speaker lineup for this track will be announced soon.
Browse all speakers →Recent Research Presented at Malignant Cancer Sessions
Selected abstracts from this track will be published here.
Related Scientific Sessions at IDC 2027
Why Attend the Malignant Cancer Conference 2027
Present Your Research
Oral and poster slots for original Malignant Cancer work, reviewed by the scientific committee.
Network Globally
Meet researchers, clinicians, and industry leaders from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Malignant Cancer research and practice.
Hybrid Flexibility
Attend in person in Rome or join virtually — same program, same certificate.
Join IDC 2027 for the Malignant Cancer track
Oral and poster slots for your work — in person in Rome or online. Not presenting? Attend as a delegate to learn from the field.
Malignant Cancer Conference 2027 — FAQs
What is the Malignant Cancer track at IDC 2027?
The Malignant Cancer track is a dedicated stream within IDC 2027 covering the latest research, clinical innovation, and best practice in Malignant Cancer. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Malignant Cancer sessions?
Researchers, clinicians, educators, doctoral students, and industry leaders with an interest in Malignant Cancer are all welcome — whether presenting or attending.
Can I present my research in the Malignant Cancer track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Malignant Cancer sessions?
Yes. IDC 2027 is a hybrid conference — attend the Malignant Cancer track in person in Rome or join live online, with on-demand access afterward.
Join the IDC 2027 delegation
Rome · June 21–23, 2027 · Hybrid · in-person & virtual
Attend without presenting.

